November 14-16, 2017
Boston, MA

LinkedIn Icon

Day One
Wednesday, November 15, 2017

Day Two
Thursday, November 16, 2017

08.00
Breakfast & Registration

09.00
Chair’s Opening Remarks

Ensuring Successful Delivery of Neoantigen Therapies

09.30
Neoantigens as Targets for Multiple Therapeutic Approaches

Synopsis

  • How can we translate neoantigens into the clinic?
  • Personalized neoantigen therapeutics: Beyond vaccines to T cell therapies
  • Inducing neoantigen-specific T cell responses ex vivo
  • Targeting shared neoantigens with precision medicine approaches

10.00
Vaccination with Great Ape Derived Adenovectors Encoding for Cancer Neoantigens Shows Potent Synergy with Immunomodulators

Synopsis

  • Adenoviral vectors can encode a large number of neoantigens
  • Vaccination with Adenovectors encoding for cancer neoantigens induce a powerful T cell response against neoantigens in mice bearing large tumors
  • Different levels of efficacy can be raised by vaccination according to selection of the immunomodulator for the combo

10.30
Neoantigens are the Achilles’ Heel of Cancer

Synopsis

  • T cells can be genetically modified to target neoantigens
  • T-cell therapy can be generated to target solid tumors

11.00
Meeting the Challenges of Personalized Medicine

  • May Pidding Director, Business Development, Ichor Medical Systems
  • James Brown VP, Corporate Development, Aldevron

Synopsis

Ichor and Aldevron will discuss how we are working together to support clients’ personalized medicine development programs.

  • Considerations for DNA, mRNA and protein production
  • Production workflow scenarios
  • Overcoming the challenges of safe and effective nucleic acid delivery
  • Development of devices suitable for commercial product deployment

Clinical Trials Case Studies

Synopsis

Hear updates on the most advanced clinical programs to discover how the application of neoantigen targets are being successfully utilised in therapeutic individualized approaches.

11.30
Morning Refreshments & Networking

12.00
Targeting Patient-Specific Neoantigens using a Personalized, Live-Attenuated Double Deleted Listeria monocytogenes (pLADD) Immunotherapy

Synopsis

  • Personalized medicine treatment approach by targeting patient-specific neoantigens
  • Rationale and preclinical and clinical data supporting the development of pLADD immunotherapy
  • pLADD clinical development strategy and update will be discussed

12.30
Exploiting NGS for Clinical Individualized Neoantigen Cancer Vaccines

  • John Castle Executive Director, Translational Medicine , Agenus

Synopsis

  • Treating cancer patients with individualized vaccines manufactured on-demand based on a NGS-profile of the patient tumor
  • Exploiting NGS, bioinformatics, and computational immunology to generate the patientspecific vaccine blueprint
  • Initial clinical data for our second-generation neoantigen vaccine platform, AutoSynVax™ (ASV™), that encodes mutation-containing peptides in a proprietary formulation and clinically tested adjuvant

13.00
Synthetic Long Peptides for Neoantigen-Specific Immunotherapy of Cancer:

Synopsis

ISA101 Trial Updates
· Clinical results including correlates with immuneresponses from trials with ISA101 in HPV16 induced cancers
· Discuss performance and approach of ISA proprietary bioinformatics pipeline ISABELLA in calling neoantigens
· Discuss ISA’s cGMP pSLP manufacturing capabilities (timelines, capacity, cost estimates) and formulation expertise

 

13.30
Lunch & Networking

14.30
Turning Up the Heat on Pancreatic Cancer: Overcoming an Immunologically Cold Landscape

  • Heather Kinkead Postdoctoral Fellow, Elizabeth Jaffee Lab , Johns Hopkins School of Medicine

Synopsis

  • Tumors that have previously been classified as low immunogenicity may have neoantigens that can be targeted by neoantigen-specific vaccines, inducing tumor-specific T cells that are not spontaneously induced by the tumor
  • The addition of treatment with antibodies specific for OX40 and PD-1 to neoantigen vaccine results in near complete tumor regression and is protective against tumor rechallenge
  • T cells that have infiltrated the tumor after combined vaccine and checkpoint therapy do not express the exhaustion markers Tim3, Lag3, or PD-1 and maintain neoantigen-specific reactivity up to 2 months post-vaccine

 

 

Vaccine Manufacturing

15.00
Development of Safe, Efficacious and Cost-Efficient Cancer Neoantigen Vaccines

Synopsis

  • Preclinical proof-of-concept: identification of neoantigens and construction of highly immunogenic and efficacious vaccines
  • Clinical studies: design consideration and execution strategy
  • Cost-efficient GMP-production of personalized neoantigen vaccines

15.30
Chairman’s Closing Remarks

15.45
Close of Congress